Literature DB >> 33718206

Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies.

Xiaofei Zhang1, Wenjun Zhang2, Pingan Cao1.   

Abstract

With the aging of the population, the incidence of colorectal cancer in China is increasing. One of the epigenetic alterations: CpG island methylator phenotype (CIMP) plays an important role in the incidence of colorectal cancer. Recent studies have shown that CIMP is closely related to some specific clinicopathological phenotypes and multiple molecular phenotypes in colorectal cancer. In this paper, the newest progress of CIMP colorectal cancer in chemotherapeutic drugs, targeted agents and small molecular methylation inhibitors are going to be introduced. We hope to provide potential clinical treatment strategies for personalized and precise treatment of colorectal cancer patients.
Copyright © 2021 Zhang, Zhang and Cao.

Entities:  

Keywords:  CpG island methylator phenotype; DNA methylation inhibitor; chemotherapy; colorectal cancer; targeted therapy

Year:  2021        PMID: 33718206      PMCID: PMC7952756          DOI: 10.3389/fonc.2021.629390

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  56 in total

1.  CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

Authors:  Xiaofei Zhang; Hideki Shimodaira; Hiroshi Soeda; Keigo Komine; Hidekazu Takahashi; Kota Ouchi; Masahiro Inoue; Masanobu Takahashi; Shin Takahashi; Chikashi Ishioka
Journal:  Int J Clin Oncol       Date:  2016-07-19       Impact factor: 3.402

2.  Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Authors:  Claire Gallois; Julien Taieb; Delphine Le Corre; Karine Le Malicot; Josep Tabernero; Claire Mulot; Jean-François Seitz; Thomas Aparicio; Gunnar Folprecht; Côme Lepage; Enrico Mini; Jean-Luc Van Laethem; Jean-François Emile; Pierre Laurent-Puig
Journal:  Clin Cancer Res       Date:  2018-06-19       Impact factor: 12.531

Review 3.  Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.

Authors:  Y Y Juo; F M Johnston; D Y Zhang; H H Juo; H Wang; E P Pappou; T Yu; H Easwaran; S Baylin; M van Engeland; N Ahuja
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

4.  Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.

Authors:  Sae-Won Han; Hyun-Jung Lee; Jeong Mo Bae; Nam-Yun Cho; Kyung-Hun Lee; Tae-Yong Kim; Do-Youn Oh; Seock-Ah Im; Yung-Jue Bang; Seung-Yong Jeong; Kyu Joo Park; Jae-Gahb Park; Gyeong Hoon Kang; Tae-You Kim
Journal:  Int J Cancer       Date:  2012-10-29       Impact factor: 7.396

5.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.

Authors:  Marius Van Rijnsoever; Hany Elsaleh; David Joseph; Kieran McCaul; Barry Iacopetta
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

Review 6.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

7.  Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Authors:  F Morano; S Corallo; M Niger; L Barault; M Milione; R Berenato; R Moretto; G Randon; M Antista; A Belfiore; A Raimondi; F Nichetti; A Martinetti; L Battaglia; F Perrone; G Pruneri; A Falcone; M Di Bartolomeo; F de Braud; F Di Nicolantonio; C Cremolini; F Pietrantonio
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

8.  Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Authors:  Nilofer S Azad; Anthony El-Khoueiry; Jun Yin; Ann L Oberg; Patrick Flynn; Douglas Adkins; Anup Sharma; Daniel J Weisenberger; Thomas Brown; Prakriti Medvari; Peter A Jones; Hariharan Easwaran; Ihab Kamel; Nathan Bahary; George Kim; Joel Picus; Henry C Pitot; Charles Erlichman; Ross Donehower; Hui Shen; Peter W Laird; Richard Piekarz; Stephen Baylin; Nita Ahuja
Journal:  Oncotarget       Date:  2017-05-23

9.  Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.

Authors:  Jeong Mo Bae; Jung Ho Kim; Yoonjin Kwak; Dae-Won Lee; Yongjun Cha; Xianyu Wen; Tae Hun Lee; Nam-Yun Cho; Seung-Yong Jeong; Kyu Joo Park; Sae Won Han; Hye Seung Lee; Tae-You Kim; Gyeong Hoon Kang
Journal:  Br J Cancer       Date:  2017-03-09       Impact factor: 7.640

10.  Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.

Authors:  Yongjun Cha; Kyung-Ju Kim; Sae-Won Han; Ye Young Rhee; Jeong Mo Bae; Xianyu Wen; Nam-Yun Cho; Dae-Won Lee; Kyung-Hun Lee; Tae-Yong Kim; Do-Youn Oh; Seock-Ah Im; Yung-Jue Bang; Seung-Yong Jeong; Kyu Joo Park; Gyeong Hoon Kang; Tae-You Kim
Journal:  Br J Cancer       Date:  2016-06-16       Impact factor: 7.640

View more
  3 in total

Review 1.  Emerging roles of cystathionine β-synthase in various forms of cancer.

Authors:  Kelly Ascenção; Csaba Szabo
Journal:  Redox Biol       Date:  2022-05-10       Impact factor: 10.787

2.  Heat selection enables highly scalable methylome profiling in cell-free DNA for noninvasive monitoring of cancer patients.

Authors:  Elsie Cheruba; Ramya Viswanathan; Pui-Mun Wong; Howard John Womersley; Shuting Han; Brenda Tay; Yiting Lau; Anna Gan; Polly S Y Poon; Anders Skanderup; Sarah B Ng; Aik Yong Chok; Dawn Qingqing Chong; Iain Beehuat Tan; Lih Feng Cheow
Journal:  Sci Adv       Date:  2022-09-09       Impact factor: 14.957

Review 3.  CpG Island Methylator Phenotype-A Hope for the Future or a Road to Nowhere?

Authors:  Karpiński Paweł; Sąsiadek Maria Małgorzata
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.